Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance

Nature Communications

Volumn 7, Issue , 2016, Pages

  Healey, Kelley R ^a   Zhao, Yanan ^a   Perez, Winder B ^a   Lockhart, Shawn R ^b   Sobel, Jack D ^c   Farmakiotis, Dimitrios ^d,e   Kontoyiannis, Dimitrios P ^d   Sanglard, Dominique ^f   Taj Aldeen, Saad J ^g   Alexander, Barbara D ^h   Jimenez Ortigosa, Cristina ^a   Shor, Erika ^a   Perlin, David S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e BROWN UNIVERSITY   (United States)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g HAMAD MEDICAL CORPORATION   (Qatar)

^h DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; DNA; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PROTEIN MSH2; TRIAZOLE; VORICONAZOLE;

ANTIMICROBIAL ACTIVITY; DRUG RESISTANCE; EMERGENCE; FUNGUS; GENE EXPRESSION; GENOTYPE; PATHOGEN; PHENOTYPE; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CONTROLLED STUDY; DNA REPAIR; FUNGAL COLONIZATION; FUNGUS ISOLATION; GENOTYPE; IN VITRO STUDY; INOCULATION; MISMATCH REPAIR; MOUSE; MULTIDRUG RESISTANCE; MUTATION; NONHUMAN; PHENOTYPE; ANIMAL; BACTERIAL COUNT; CANDIDIASIS; DISEASE MODEL; DRUG EFFECTS; FUNGAL GENE; GENE DELETION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; KIDNEY; MICROBIOLOGY; PATHOLOGY;

CANDIDA GLABRATA;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, MULTIPLE; ECHINOCANDINS; GENE DELETION; GENES, FUNGAL; GENOTYPE; HUMANS; KIDNEY; MICE; MUTATION; PHENOTYPE;

EID: 84962675422     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11128     Document Type: Article

References (36)

1. Pfaller, M. A., Diekema, D. J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36, 1-53 (2010).
2. Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004).
3. Sabra, R., Branch, R. A. Amphotericin B nephrotoxicity. Drug Saf. 5, 94-108 (1990).
4. Diekema, D., Arbefeville, S., Boyken, L., Kroeger, J., Pfaller, M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn. Microbiol. Infect. Dis. 73, 45-48 (2012).
5. Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., Castanheira, M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob. Agents Chemother. 55, 561-566 (2011).
6. Alexander, B. D. et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56, 1724-1732 (2013).
7. Pfaller, M. A., Diekema, D. J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20, 133-163 (2007).
8. Pfaller, M. A. et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 50, 1199-1203 (2012).
9. Farmakiotis, D., Tarrand, J. J., Kontoyiannis, D. P. Drug-resistant Candida glabrata infection in cancer patients. Emerg. Infect. Dis. 20, 1833-1840 (2014).
10. Bizerra, F. C. et al. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Antimicrob. Agents Chemother. 58, 2438-2440 (2014).
11. Pham, C. D. et al. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob. Agents Chemother. 58, 4690-4696 (2014).
12. Cho, E. J. et al. Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia. J. Antimicrob. Chemother. 70, 1268-1270 (2015).
13. Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., Perlin, D. S. Mechanisms of antifungal drug resistance. Cold Spring Harb. Perspect. Med. 5, a019752 (2014).
14. Chopra, I., O'Neill, A. J., Miller, K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug. Resist. Updat 6, 137-145 (2003).
15. Legrand, M., Chan, C. L., Jauert, P. A., Kirkpatrick, D. T. Role of DNA mismatch repair and double-strand break repair in genome stability and antifungal drug resistance in Candida albicans. Eukaryot. Cell 6, 2194-2205 (2007).
16. Perlin, D. S. Mechanisms of echinocandin antifungal drug resistance. Ann. NY. Acad. Sci. 1354, 1-11 (2015).
17. Vermitsky, J. P. et al. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. Mol. Microbiol. 61, 704-722 (2006).
18. Tsai, H. F., Krol, A. A., Sarti, K. E., Bennett, J. E. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob. Agents Chemother. 50, 1384-1392 (2006).
19. Vandeputte, P. et al. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob. Agents Chemother. 51, 982-990 (2007).
20. Vandeputte, P. et al. A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata. Antimicrob. Agents Chemother. 52, 3701-3709 (2008).
21. National Commitee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard 3rd ed, Vol. 28 (Clinical and Laboratory Standards Institute document M27-S4, 2012).
22. Pfaller, M. A., Diekema, D. J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010-2012. J. Clin. Microbiol. 50, 2846-2856 (2012).
23. Mendillo, M. L. et al. A conserved MutS homolog connector domain interface interacts with MutL homologs. Proc. Natl Acad. Sci. USA 106, 22223-22228 (2009).
24. Briones-Martin-del-Campo, M. et al. The superoxide dismutases of Candida glabrata protect against oxidative damage and are required for lysine biosynthesis, DNA integrity and chronological life survival. Microbiology 161, 300-310 (2015).
25. Arendrup, M. C. et al. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56, 2435-2442 (2012).
26. Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., Perlin, D. S. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53, 3690-3699 (2009).
27. Perlin, D. S. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs 74, 1573-1585 (2014).
28. Pultz, N. J., Stiefel, U., Ghannoum, M., Helfand, M. S., Donskey, C. J. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob. Agents Chemother. 49, 438-440 (2005).
29. Beyda, N. D., Liao, G., Endres, B. T., Lewis, R. E., Garey, K. W. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob. Agents Chemother. 59, 5405-5412 (2015).
30. Vale-Silva, L., Ischer, F., Leibundgut-Landmann, S., Sanglard, D. Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells. Infect. Immun. 81, 1709-1720 (2013).
31. Magditch, D. A., Liu, T. B., Xue, C., Idnurm, A. DNA mutations mediate microevolution between host-adapted forms of the pathogenic fungus Cryptococcus neoformans. PLoS Pathog. 8, e1002936 (2012).
32. Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., Sanglard, D. Contribution of CgPDR1-regulated genes in enhanced virulence of azoleresistant Candida glabrata. PLoS ONE 6, e17589 (2011).
33. Shapiro, R. S. Antimicrobial-induced DNA damage and genomic instability in microbial pathogens. PLoS Pathog. 11, e1004678 (2015).
34. Zordan, R. E. et al. Expression plasmids for use in Candida glabrata. G3 (Bethesda) 3, 1675-1686 (2013).
35. Jacobsen, I. D. et al. Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy. Infect. Immun. 78, 1066-1077 (2010).
36. Healey, K. R., Katiyar, S. K., Raj, S., Edlind, T. D. CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction. Mol. Microbiol. 86, 303-313 (2012).